Cytarabine (over the dose range of 0.1–0.5 μM) in combination with MP-A08 liposomes showed significant synergistic effects (as confirmed by the Chou–Talalay Combination Index) against the chemosensitised human AML cell lines MV4-11 and OCI-AML3. Here, RUNX2 is linked to acute myeloid leukemia.